BFM
BHVN

Boothbay Fund Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Boothbay Fund Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,600
Closed -$1.89M – 2490
2021
Q3 		$1.89M Buy
+13,600
New +$1.7M 0.05% 472
2021
Q1 		– Sell
-108
Closed -$926K – 2023
2020
Q4 		$926K Buy
+108
New +$9.15K 0.03% 518
2019
Q3 		– Sell
-383
Closed -$1.68M – 1027
2019
Q2 		$1.68M Buy
383
+328
+596% +$18.5K 0.15% 171
2019
Q1 		$283K Hold
55
– – 0.03% 518
2018
Q4 		$203K Buy
+55
New +$1.98K 0.03% 492
2018
Q2 		– Sell
-174
Closed -$448K – 1014
2018
Q1 		$448K Sell
174
-3
-2% -$90 0.05% 352
2017
Q4 		$478K Buy
177
+108
+157% +$2.97K 0.07% 278
2017
Q3 		$258K Buy
+69
New +$2.09K 0.04% 425

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Boothbay Fund Management's BHVN Position: Q4 2022 in Review

Boothbay Fund Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 9,552 shares — an estimated $1.44M sold.

Boothbay Fund Management first reported a position in BHVN in Q1 2018 and held it in 6 quarters. The position peaked at $1.44M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Boothbay Fund Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 9,552 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.44M.
  • Boothbay Fund Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 6 quarters.
  • Boothbay Fund Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.44M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.